Index RUT P/E - EPS (ttm) - Insider Own 41.29% Shs Outstand 34.20M Perf Week 0.23%
Market Cap 155.22M Forward P/E - EPS next Y -4.70 Insider Trans 21.69% Shs Float 21.05M Perf Month -5.25%
Income - PEG - EPS next Q -1.90 Inst Own 31.08% Short Float 9.47% Perf Quarter -76.06%
Sales - P/S - EPS this Y -35.71% Inst Trans -6.59% Short Ratio 2.70 Perf Half Y -
Book/sh 9.17 P/B 0.47 EPS next Y 17.79% ROA - Short Interest 1.99M Perf Year -
Cash/sh 9.33 P/C 0.46 EPS next 5Y - ROE - 52W Range 3.85 - 26.62 Perf YTD -25.22%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -83.73% Beta -
Dividend TTM - Quick Ratio 17.63 Sales past 5Y 0.00% Gross Margin - 52W Low 12.47% ATR (14) 0.33
Dividend Ex-Date - Current Ratio 17.63 EPS Y/Y TTM - Oper. Margin - RSI (14) 41.80 Volatility 6.26% 6.38%
Employees - Debt/Eq 0.03 Sales Y/Y TTM - Profit Margin - Recom 3.50 Target Price 6.33
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q -36.08% Payout - Rel Volume 0.14 Prev Close 4.55
Sales Surprise - EPS Surprise 0.00% Sales Q/Q - Earnings Feb 26 Avg Volume 737.66K Price 4.33
SMA20 -2.00% SMA50 -10.84% SMA200 -64.80% Trades
Volume 106,692 Change -4.84%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-28-25 Initiated William Blair
Mkt Perform
Dec-10-24 Downgrade Morgan Stanley
Overweight → Underweight
$40 → $5
Dec-09-24 Downgrade Jefferies
Buy → Hold
$42 → $7
Dec-09-24 Downgrade Citigroup
Buy → Neutral
$45 → $7
Oct-21-24 Initiated Morgan Stanley
Overweight
$40
Oct-21-24 Initiated Jefferies
Buy
$42
Oct-21-24 Initiated Citigroup
Buy
$45
Mar-04-25 05:07AM
Feb-20-25 04:30PM
10:36AM
Feb-16-25 07:18AM
Feb-14-25 05:45AM
08:42AM
Loading…
Feb-13-25 08:42AM
Feb-07-25 05:45AM
Jan-30-25 09:01AM
Jan-29-25 05:39AM
Jan-28-25 07:27PM
09:00AM
Jan-24-25 05:45AM
Jan-22-25 03:00AM
Jan-21-25 05:45AM
Jan-18-25 03:07AM
09:00PM
Loading…
Jan-06-25 09:00PM
Jan-03-25 12:51PM
Jan-02-25 09:35AM
Jan-01-25 05:00AM
Dec-27-24 11:32AM
09:18AM
Dec-26-24 07:23AM
Dec-25-24 07:04AM
Dec-23-24 10:19AM
Dec-19-24 01:15PM
05:46AM
(Pharmaceutical Technology)
Dec-18-24 09:00AM
Dec-16-24 04:20PM
03:00AM
Dec-13-24 10:31AM
06:34PM
Loading…
Dec-12-24 06:34PM
Dec-09-24 07:51PM
09:28AM
07:41AM
Dec-07-24 06:34AM
Dec-06-24 04:35PM
(GlobeNewswire) +9.36%
-76.85%
Dec-05-24 04:30PM
Dec-04-24 04:47PM
Nov-21-24 04:30PM
Nov-12-24 11:01PM
Nov-07-24 04:30PM
(GlobeNewswire) -10.11%
+7.61%
Nov-04-24 09:00AM
Oct-24-24 09:00AM
Oct-21-24 10:53AM
Oct-17-24 09:45AM
Oct-12-24 02:31PM
Oct-07-24 09:10PM
Oct-05-24 07:15AM
Oct-03-24 09:05AM
Oct-01-24 04:30PM
Sep-26-24 04:08PM
(Investor's Business Daily)
02:36PM
08:25AM
Sep-25-24 08:00PM
04:13PM
11:27AM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Barton Shane Principal Accounting Officer Sep 27 '24 Buy 18.00 2,632 47,376 2,632 Mar 10 04:10 PM Pande Vijay Satyanand Director Oct 01 '24 Buy 19.73 126,793 2,501,626 1,026,793 Oct 03 07:19 PM Pande Vijay Satyanand Director Oct 02 '24 Buy 19.73 67,096 1,323,804 1,093,889 Oct 03 07:19 PM Pande Vijay Satyanand Director Oct 03 '24 Buy 19.90 25,306 503,589 1,119,195 Oct 03 07:19 PM Cormorant Asset Management, LP Former 10% Owner Sep 27 '24 Buy 18.00 450,000 8,100,000 1,629,529 Oct 01 04:01 PM Pande Vijay Satyanand Director Sep 27 '24 Buy 18.00 900,000 16,200,000 900,000 Sep 27 04:28 PM ENRIGHT PATRICK G Director Sep 27 '24 Buy 18.00 400,000 7,200,000 1,710,589 Sep 27 04:26 PM HEALY JAMES Director Sep 27 '24 Buy 18.00 666,665 11,999,970 2,227,124 Sep 27 04:22 PM
Index RUT P/E - EPS (ttm) - Insider Own 52.26% Shs Outstand 36.58M Perf Week 15.66%
Market Cap 302.49M Forward P/E - EPS next Y -3.90 Insider Trans 0.00% Shs Float 17.46M Perf Month -50.63%
Income - PEG - EPS next Q -0.71 Inst Own 54.31% Short Float 9.52% Perf Quarter -61.64%
Sales - P/S - EPS this Y 12.17% Inst Trans 0.18% Short Ratio 10.02 Perf Half Y -61.03%
Book/sh 8.83 P/B 0.94 EPS next Y -16.34% ROA - Short Interest 1.66M Perf Year -
Cash/sh 8.77 P/C 0.94 EPS next 5Y -10.80% ROE - 52W Range 6.43 - 29.74 Perf YTD -53.38%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -72.19% Beta -
Dividend TTM - Quick Ratio 45.91 Sales past 5Y 0.00% Gross Margin - 52W Low 28.62% ATR (14) 1.61
Dividend Ex-Date - Current Ratio 45.91 EPS Y/Y TTM - Oper. Margin - RSI (14) 33.94 Volatility 27.85% 15.69%
Employees 58 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 37.33
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -185.25% Payout - Rel Volume 2.13 Prev Close 8.59
Sales Surprise - EPS Surprise 0.00% Sales Q/Q - Earnings Feb 26 Avg Volume 165.80K Price 8.27
SMA20 -31.86% SMA50 -42.81% SMA200 -58.77% Trades
Volume 352,649 Change -3.73%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-02-24 Initiated TD Cowen
Buy
Jul-02-24 Initiated Stifel
Buy
$35
Jul-02-24 Initiated Jefferies
Buy
$35
Mar-03-25 07:00AM
Feb-24-25 07:00AM
Jan-10-25 07:20AM
Jan-09-25 09:12AM
07:00AM
12:01PM
Loading…
Dec-06-24 12:01PM
Nov-14-24 07:00AM
Nov-08-24 07:18AM
Nov-07-24 07:00AM
Nov-04-24 07:00AM
Sep-05-24 07:00AM
Aug-29-24 07:00AM
Aug-08-24 07:00AM
Aug-06-24 06:30AM
Jul-29-24 07:00AM
02:22PM
Loading…
Jul-05-24 02:22PM
Jun-12-24 04:01PM
Jun-06-24 06:54PM
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HEALY JAMES Director Jul 01 '24 Buy 24.52 44,032 1,079,575 40,851 Jul 03 08:04 PM HEALY JAMES Director Jun 10 '24 Buy 17.00 558,824 9,500,008 1,863,327 Jun 10 07:38 PM
Index RUT P/E - EPS (ttm) -2.40 Insider Own 42.87% Shs Outstand 33.71M Perf Week -1.36%
Market Cap 739.17M Forward P/E - EPS next Y -3.70 Insider Trans 0.00% Shs Float 19.43M Perf Month -20.64%
Income -80.49M PEG - EPS next Q -0.66 Inst Own 59.13% Short Float 21.56% Perf Quarter -25.71%
Sales 0.00M P/S - EPS this Y -20.55% Inst Trans 20.51% Short Ratio 26.12 Perf Half Y -18.31%
Book/sh 7.64 P/B 2.84 EPS next Y -19.98% ROA -36.75% Short Interest 4.19M Perf Year 7.31%
Cash/sh 6.43 P/C 3.38 EPS next 5Y -1.03% ROE -39.36% 52W Range 14.35 - 36.37 Perf YTD -18.43%
Dividend Est. - P/FCF - EPS past 5Y - ROI -31.24% 52W High -40.25% Beta 1.16
Dividend TTM - Quick Ratio 13.14 Sales past 5Y 0.00% Gross Margin - 52W Low 51.43% ATR (14) 1.41
Dividend Ex-Date - Current Ratio 13.14 EPS Y/Y TTM -15.71% Oper. Margin - RSI (14) 28.74 Volatility 4.68% 5.72%
Employees 52 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 40.40
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q 3.26% Payout - Rel Volume 0.70 Prev Close 21.87
Sales Surprise - EPS Surprise 9.79% Sales Q/Q - Earnings Mar 03 BMO Avg Volume 160.37K Price 21.73
SMA20 -12.38% SMA50 -16.65% SMA200 -12.35% Trades
Volume 112,059 Change -0.64%
Index - P/E - EPS (ttm) -1.53 Insider Own 5.49% Shs Outstand 132.65M Perf Week -7.32%
Market Cap 17.93B Forward P/E - EPS next Y -0.66 Insider Trans -9.69% Shs Float 127.76M Perf Month -24.27%
Income -190.43M PEG - EPS next Q -0.62 Inst Own 90.83% Short Float 1.95% Perf Quarter -23.78%
Sales 1.70B P/S 10.57 EPS this Y -39.08% Inst Trans 2.78% Short Ratio 1.60 Perf Half Y 12.88%
Book/sh 9.01 P/B 14.72 EPS next Y 69.04% ROA -12.12% Short Interest 2.49M Perf Year 47.01%
Cash/sh 7.16 P/C 18.52 EPS next 5Y - ROE -19.42% 52W Range 83.13 - 183.00 Perf YTD -16.22%
Dividend Est. - P/FCF 258.95 EPS past 5Y 3.18% ROI -14.74% 52W High -27.52% Beta 1.82
Dividend TTM - Quick Ratio 3.87 Sales past 5Y 41.83% Gross Margin 60.30% 52W Low 59.55% ATR (14) 9.23
Dividend Ex-Date - Current Ratio 4.00 EPS Y/Y TTM 59.77% Oper. Margin -13.10% RSI (14) 26.66 Volatility 6.98% 5.90%
Employees 4434 Debt/Eq 0.16 Sales Y/Y TTM 56.75% Profit Margin -11.22% Recom 1.45 Target Price 196.95
Option/Short Yes / Yes LT Debt/Eq 0.08 EPS Q/Q 37.44% Payout - Rel Volume 1.68 Prev Close 140.66
Sales Surprise 9.29% EPS Surprise -7.56% Sales Q/Q 53.02% Earnings Feb 27 AMC Avg Volume 1.56M Price 132.63
SMA20 -16.21% SMA50 -19.41% SMA200 -1.95% Trades
Volume 2,612,927 Change -5.71%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-23-25 Initiated Barclays
Overweight
$200
Jun-03-24 Resumed Jefferies
Buy
$142
Apr-08-24 Resumed Craig Hallum
Buy
$117
Feb-20-24 Downgrade Raymond James
Strong Buy → Outperform
$68 → $85
Dec-29-23 Reiterated BTIG Research
Buy
$75 → $85
Dec-14-23 Initiated Guggenheim
Buy
$70
Dec-13-23 Initiated Wolfe Research
Outperform
$70
Nov-13-23 Upgrade Raymond James
Outperform → Strong Buy
$68
Sep-28-23 Initiated Bernstein
Mkt Perform
$48
Jul-05-23 Resumed JP Morgan
Overweight
$85
May-05-23 Initiated UBS
Buy
$76
Jan-18-23 Upgrade Raymond James
Mkt Perform → Outperform
$58
Aug-25-22 Initiated Credit Suisse
Outperform
$70
Apr-25-22 Initiated Stephens
Overweight
$54
Mar-08-22 Initiated Goldman
Buy
$90
Jan-06-22 Resumed Piper Sandler
Overweight
$110
Oct-15-21 Resumed Cowen
Outperform
$150
Jun-15-21 Initiated Raymond James
Mkt Perform
May-25-21 Initiated Wells Fargo
Overweight
$110
Jan-28-21 Initiated Truist
Buy
$143
Show Previous Ratings
Today 08:00AM
Mar-07-25 09:30AM
Mar-04-25 07:00AM
Feb-28-25 10:35AM
(Thomson Reuters StreetEvents)
02:37AM
06:20PM
Loading…
Feb-27-25 06:20PM
04:53PM
04:05PM
Feb-26-25 08:14AM
07:08AM
Feb-25-25 06:00AM
Feb-24-25 02:19PM
Feb-19-25 09:55AM
Feb-18-25 09:00AM
Feb-14-25 03:47PM
(Investor's Business Daily)
02:51PM
Loading…
Feb-10-25 02:51PM
07:00AM
Feb-03-25 07:00AM
Jan-28-25 08:02AM
Jan-27-25 09:42AM
Jan-25-25 10:05AM
Jan-21-25 06:05PM
04:03PM
(Investor's Business Daily)
Jan-17-25 09:00AM
Jan-16-25 04:05PM
(Investor's Business Daily)
Jan-15-25 07:00AM
Jan-12-25 07:20PM
Jan-09-25 08:15AM
Jan-07-25 09:00AM
Jan-03-25 02:03PM
(Investor's Business Daily)
09:35AM
Loading…
Dec-17-24 09:35AM
08:00AM
06:53AM
Dec-13-24 08:21AM
Dec-12-24 08:00AM
Dec-09-24 08:00AM
Dec-03-24 08:06AM
Dec-02-24 02:40PM
08:00AM
08:00AM
05:00AM
Nov-27-24 09:00AM
Nov-25-24 07:57PM
05:09PM
03:51PM
09:00AM
09:00AM
Nov-21-24 05:31PM
Nov-14-24 09:09PM
Nov-13-24 10:25AM
02:17AM
12:04AM
Nov-12-24 06:30PM
05:55PM
04:48PM
(Associated Press Finance)
04:05PM
07:00AM
Nov-11-24 07:03AM
Nov-08-24 09:00AM
Nov-01-24 09:00AM
Oct-23-24 12:00PM
Oct-22-24 09:00AM
Oct-06-24 09:12AM
Sep-23-24 04:06PM
10:07AM
Sep-16-24 07:13AM
05:17AM
Sep-14-24 02:16PM
Sep-11-24 05:59AM
Sep-09-24 11:42AM
(Investor's Business Daily)
Sep-08-24 08:22PM
Sep-06-24 10:24AM
Sep-03-24 02:37AM
Aug-31-24 11:48AM
Aug-29-24 02:07PM
Aug-28-24 09:00AM
Aug-27-24 03:19PM
03:16PM
Aug-17-24 01:01AM
Aug-10-24 01:01AM
Aug-09-24 09:46AM
(Thomson Reuters StreetEvents) +6.38%
Aug-08-24 07:00PM
05:19PM
(Associated Press Finance)
04:05PM
Aug-06-24 09:00AM
Jul-30-24 04:05PM
Jul-29-24 10:53AM
Jul-27-24 01:00AM
Jul-26-24 08:00AM
Jul-25-24 10:02AM
Jul-18-24 01:00AM
Jul-08-24 09:00AM
Jul-03-24 08:53AM
07:00AM
05:30AM
Jun-27-24 07:00AM
Jun-19-24 03:10AM
Jun-17-24 07:00AM
Jun-10-24 02:25PM
Jun-03-24 08:00AM
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Mar 05 '25 Sale 143.29 6,000 859,734 143,768 Mar 07 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Mar 05 '25 Sale 143.40 87,272 12,515,006 203,354 Mar 07 09:35 PM SOLOMON MOSHKEVICH Officer Mar 05 '25 Proposed Sale 143.29 6,000 859,734 Mar 05 04:32 PM STEVEN L CHAPMAN Officer Mar 05 '25 Proposed Sale 143.40 87,272 12,515,001 Mar 05 04:17 PM Sheena Jonathan CO-FOUNDER Feb 26 '25 Sale 160.47 3,000 481,419 43,282 Feb 28 09:05 PM Sheena Jonathan CO-FOUNDER Feb 26 '25 Sale 160.54 2,700 433,455 260,789 Feb 28 09:05 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Feb 06 '25 Sale 177.77 1,632 290,121 149,768 Feb 07 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Feb 06 '25 Sale 177.77 663 117,862 156,044 Feb 07 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Feb 03 '25 Sale 176.88 43,502 7,694,642 70,629 Feb 04 09:45 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 31 '25 Sale 173.05 400 69,220 114,131 Feb 04 09:45 PM MICHAEL BURKES BROPHY Officer Feb 03 '25 Proposed Sale 176.92 43,902 7,767,142 Feb 03 04:22 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 29 '25 Sale 165.87 4,335 719,044 103,697 Jan 31 09:45 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 31 '25 Sale 176.60 1,886 333,068 101,811 Jan 31 09:45 PM Sheena Jonathan CO-FOUNDER Jan 29 '25 Sale 165.87 1,054 174,827 260,103 Jan 31 09:35 PM Sheena Jonathan CO-FOUNDER Jan 31 '25 Sale 176.60 163 28,786 259,940 Jan 31 09:35 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Jan 29 '25 Sale 165.87 6,003 995,716 2,383,177 Jan 31 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jan 29 '25 Sale 165.87 4,773 791,694 213,020 Jan 31 09:35 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Jan 29 '25 Sale 165.87 5,201 862,688 135,483 Jan 31 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Jan 29 '25 Sale 165.87 4,030 668,454 143,200 Jan 31 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Jan 29 '25 Sale 165.87 13,685 2,269,928 253,944 Jan 31 09:35 PM MICHAEL BURKES BROPHY Officer Jan 31 '25 Proposed Sale 176.27 1,886 332,445 Jan 31 04:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 27 '25 Sale 161.87 1,442 233,417 108,032 Jan 29 09:45 PM MICHAEL BURKES BROPHY Officer Jan 27 '25 Proposed Sale 167.61 1,442 241,694 Jan 27 04:24 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 24 '25 Sale 171.98 946 162,689 109,474 Jan 24 09:45 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 23 '25 Sale 171.09 495 84,690 110,420 Jan 24 09:45 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Jan 22 '25 Sale 164.97 24,861 4,101,226 140,684 Jan 24 09:45 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Jan 22 '25 Sale 164.97 21,228 3,501,905 147,230 Jan 24 09:45 PM MICHAEL BURKES BROPHY Officer Jan 24 '25 Proposed Sale 171.82 946 162,542 Jan 24 04:18 PM Sheena Jonathan CO-FOUNDER Jan 22 '25 Sale 165.00 971 160,214 261,745 Jan 22 09:45 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jan 22 '25 Sale 164.97 22,039 3,635,685 217,793 Jan 22 09:45 PM Chapman Steven Leonard CEO AND PRESIDENT Jan 22 '25 Sale 164.97 78,553 12,958,585 267,629 Jan 22 09:45 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 22 '25 Sale 164.97 25,931 4,277,735 109,665 Jan 22 09:45 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jan 08 '25 Sale 175.30 6,223 1,090,901 199,804 Jan 10 09:35 PM DANIEL RABINOWITZ Officer Jan 08 '25 Proposed Sale 170.40 6,223 1,060,399 Jan 08 04:23 PM Sheena Jonathan CO-FOUNDER Jan 02 '25 Sale 159.55 3,000 478,645 44,782 Jan 03 09:55 PM Sheena Jonathan CO-FOUNDER Jan 02 '25 Sale 159.44 2,700 430,480 254,372 Jan 03 09:55 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Dec 23 '24 Sale 159.60 669 106,773 114,142 Dec 26 09:05 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Dec 23 '24 Sale 159.60 2,428 387,511 116,997 Dec 26 09:05 PM Sheena Jonathan CO-FOUNDER Dec 18 '24 Sale 167.24 3,000 501,713 46,282 Dec 20 09:05 PM Sheena Jonathan CO-FOUNDER Dec 18 '24 Sale 167.27 2,700 451,625 257,072 Dec 20 09:05 PM Sheena Jonathan Director Dec 18 '24 Proposed Sale 150.00 17,100 2,565,000 Dec 18 11:33 AM Rabinowitz Matthew EXECUTIVE CHAIRMAN Dec 13 '24 Sale 165.74 160,000 26,518,750 2,389,180 Dec 13 09:35 PM MATTHEW RABINOWITZ Director Dec 13 '24 Proposed Sale 166.45 160,000 26,632,000 Dec 13 04:25 PM Chapman Rowan E Director Dec 10 '24 Sale 170.24 1,767 300,808 6,202 Dec 11 09:05 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Dec 09 '24 Sale 166.59 4,858 809,312 114,912 Dec 11 09:05 PM Chapman Rowan E Officer Dec 10 '24 Proposed Sale 170.24 1,767 300,808 Dec 10 03:08 PM Moshkevich Solomon Officer Dec 09 '24 Proposed Sale 166.59 4,858 809,312 Dec 10 02:41 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Dec 05 '24 Option Exercise 5.40 68,496 369,556 2,549,180 Dec 09 04:05 PM BOTHA ROELOF Director Dec 02 '24 Sale 169.12 87,473 14,793,563 1,224,787 Dec 04 05:13 PM BV369 TRUST Director Dec 02 '24 Proposed Sale 169.12 87,473 14,793,565 Dec 02 04:58 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Nov 25 '24 Sale 168.51 2,000 337,028 86,000 Nov 27 09:05 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Nov 26 '24 Sale 164.17 2,000 328,348 84,000 Nov 27 09:05 PM THE TINKERBELLE TRUST U/A DTD Officer Nov 26 '24 Proposed Sale 164.17 2,000 328,348 Nov 26 04:36 PM THE TINKERBELLE TRUST U/A DTD Officer Nov 25 '24 Proposed Sale 168.51 2,000 337,028 Nov 25 06:37 PM Marcus Gail Boxer Director Nov 19 '24 Sale 159.98 9,682 1,548,931 9,704 Nov 21 09:35 PM Marcus Gail Boxer Director Nov 19 '24 Proposed Sale 159.98 9,682 1,548,931 Nov 19 05:19 PM Baynes Roy D. Director Nov 15 '24 Option Exercise 23.48 37,230 874,177 53,037 Nov 15 09:50 PM Baynes Roy D. Director Nov 15 '24 Sale 146.11 37,230 5,439,565 15,807 Nov 15 09:50 PM Chapman Steven Leonard CEO AND PRESIDENT Nov 15 '24 Sale 146.41 4,728 692,209 185,034 Nov 15 09:50 PM Sheena Jonathan CO-FOUNDER Nov 13 '24 Sale 153.54 20,000 3,070,769 259,772 Nov 15 09:05 PM Sheena Jonathan CO-FOUNDER Nov 13 '24 Sale 156.48 16,300 2,550,628 47,782 Nov 15 09:05 PM Marcus Gail Boxer Director Nov 14 '24 Sale 158.53 2,212 350,672 19,386 Nov 15 09:05 PM ROY D BAYNES Director Nov 15 '24 Proposed Sale 146.11 37,230 5,439,564 Nov 15 04:00 PM STEVEN L CHAPMAN Officer Nov 15 '24 Proposed Sale 146.41 4,728 692,209 Nov 15 04:00 PM Marcus Gail Boxer Director Nov 14 '24 Proposed Sale 158.53 2,212 350,672 Nov 14 05:37 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Nov 11 '24 Option Exercise 5.40 130,000 701,389 2,470,684 Nov 13 09:50 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Nov 12 '24 Option Exercise 5.40 10,000 53,953 2,480,684 Nov 13 09:50 PM Sheena Jonathan Director Nov 13 '24 Proposed Sale 154.86 36,300 5,621,395 Nov 13 10:27 AM Sheena Jonathan CO-FOUNDER Nov 08 '24 Sale 130.77 3,000 392,306 55,932 Nov 12 09:05 PM Sheena Jonathan CO-FOUNDER Nov 08 '24 Sale 130.80 2,700 353,165 279,772 Nov 12 09:05 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 31 '24 Sale 126.45 1,866 235,956 68,851 Nov 01 09:35 PM MICHAEL BURKES BROPHY Officer Oct 31 '24 Proposed Sale 126.73 1,866 236,478 Oct 31 04:27 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Oct 28 '24 Sale 118.21 1,057 124,948 206,027 Oct 30 09:35 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Oct 28 '24 Sale 118.21 1,196 141,380 110,695 Oct 30 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Oct 28 '24 Sale 118.21 929 109,818 113,136 Oct 30 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Oct 28 '24 Sale 118.21 3,960 468,114 189,762 Oct 30 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 28 '24 Sale 118.21 1,238 146,345 71,471 Oct 30 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 29 '24 Sale 119.93 754 90,427 70,717 Oct 30 09:35 PM MICHAEL BURKES BROPHY Officer Oct 29 '24 Proposed Sale 120.71 754 91,015 Oct 29 04:22 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 24 '24 Sale 119.19 914 108,940 73,400 Oct 25 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 25 '24 Sale 118.81 691 82,098 72,709 Oct 25 09:35 PM MICHAEL BURKES BROPHY Officer Oct 24 '24 Proposed Sale 118.65 1,605 190,433 Oct 24 04:21 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Oct 21 '24 Sale 120.76 294 35,503 112,147 Oct 23 09:35 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Oct 22 '24 Sale 120.07 256 30,738 111,891 Oct 23 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Oct 21 '24 Sale 120.76 342 41,299 114,264 Oct 23 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Oct 22 '24 Sale 120.07 199 23,894 114,065 Oct 23 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 23 '24 Sale 119.09 496 59,068 74,314 Oct 23 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Oct 21 '24 Sale 120.76 467 56,394 207,433 Oct 22 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Oct 22 '24 Sale 120.07 349 41,904 207,084 Oct 22 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Oct 21 '24 Sale 120.76 1,709 206,375 194,615 Oct 22 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Oct 22 '24 Sale 120.07 893 107,223 193,722 Oct 22 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 21 '24 Sale 120.76 608 73,420 74,014 Oct 22 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Oct 22 '24 Sale 120.07 454 54,512 73,560 Oct 22 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Oct 15 '24 Sale 130.40 4,523 589,797 191,163 Oct 17 09:05 PM STEVEN L CHAPMAN Officer Oct 15 '24 Proposed Sale 130.40 4,523 589,797 Oct 15 04:29 PM Sheena Jonathan CO-FOUNDER Oct 01 '24 Sale 125.67 3,000 377,024 57,432 Oct 03 09:05 PM Sheena Jonathan CO-FOUNDER Oct 01 '24 Sale 125.60 2,700 339,113 282,041 Oct 03 09:05 PM Sheena Jonathan CO-FOUNDER Sep 18 '24 Sale 127.61 19,300 2,462,787 58,932 Sep 20 09:35 PM Sheena Jonathan CO-FOUNDER Sep 18 '24 Sale 127.57 2,700 344,450 284,741 Sep 20 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Sep 16 '24 Sale 128.48 5,024 645,474 195,686 Sep 18 09:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
